Literature DB >> 22025158

Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?

Alan L Ho, Gary K Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22025158      PMCID： PMC3675677          DOI： 10.1200/JCO.2011.38.2374

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

1.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

2.  Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

Authors:  Katia Scotlandi; Maria Cristina Manara; Giordano Nicoletti; Pier-Luigi Lollini; Stella Lukas; Stefania Benini; Stefania Croci; Stefania Perdichizzi; Diana Zambelli; Massimo Serra; Carlos García-Echeverría; Francesco Hofmann; Piero Picci
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

3.  The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.

Authors:  J A Toretsky; T Kalebic; V Blakesley; D LeRoith; L J Helman
Journal:  J Biol Chem       Date:  1997-12-05       Impact factor: 5.157

4.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Authors:  X Wan; B Harkavy; N Shen; P Grohar; L J Helman
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

5.  Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Authors:  Heribert Juergens; Najat C Daw; Birgit Geoerger; Stefano Ferrari; Milena Villarroel; Isabelle Aerts; Jeremy Whelan; Uta Dirksen; Mary L Hixon; Donghua Yin; Tao Wang; Stephanie Green; Luisa Paccagnella; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

Review 6.  Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.

Authors:  A Grimberg; P Cohen
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

7.  Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas.

Authors:  A Sekyi-Otu; R S Bell; C Ohashi; M Pollak; I L Andrulis
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

8.  Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.

Authors:  Jiping Zha; Carol O'Brien; Heidi Savage; Ling-Yuh Huw; Fiona Zhong; Leanne Berry; Gail D Lewis Phillips; Elizabeth Luis; Guy Cavet; Xiaolan Hu; Lukas C Amler; Mark R Lackner
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 9.  The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer.

Authors:  Antonino Belfiore
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

10.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Authors:  Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; Jose Baselga; Neal Rosen
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701
View more
  15 in total

1.  Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.

Authors:  Sudan N Loganathan; Nan Tang; Albert E Holler; Nenghui Wang; Jialiang Wang
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

2.  Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.

Authors:  A C M van de Luijtgaarden; Y M H Versleijen-Jonkers; M H S Roeffen; H W B Schreuder; U E Flucke; W T A van der Graaf
Journal:  Target Oncol       Date:  2013-01-06       Impact factor: 4.493

3.  Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Authors:  Josep Tabernero; Sant P Chawla; Hedy Kindler; Karen Reckamp; E Gabriela Chiorean; Nilofer S Azad; A Craig Lockhart; Cheng-Pang Hsu; Nigel F Baker; Francesco Galimi; Pedro Beltran; José Baselga
Journal:  Target Oncol       Date:  2014-05-11       Impact factor: 4.493

4.  Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.

Authors:  Andreas Pettersson; Rosina T Lis; Allison Meisner; Richard Flavin; Edward C Stack; Michelangelo Fiorentino; Stephen Finn; Rebecca E Graff; Kathryn L Penney; Jennifer R Rider; Elizabeth J Nuttall; Neil E Martin; Howard D Sesso; Michael Pollak; Meir J Stampfer; Philip W Kantoff; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci
Journal:  J Natl Cancer Inst       Date:  2013-11-30       Impact factor: 13.506

5.  Targeted therapies for bone sarcomas.

Authors:  Dominique Heymann; Françoise Rédini
Journal:  Bonekey Rep       Date:  2013-07-17

Review 6.  Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

Authors:  Cormac Owens; Lesleigh S Abbott; Abha A Gupta
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

7.  Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.

Authors:  Mark A Applebaum; Dafydd G Thomas; Todd Hembrough; Jon Burrows; Andrew E Horvai; Elizabeth R Lawlor; Steven G DuBois
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-09

8.  A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells.

Authors:  Frans van Valen; Henning Harrer; Marc Hotfilder; Uta Dirksen; Thomas Pap; George Gosheger; Hans-Ulrich Humpf; Heribert Jürgens
Journal:  Sarcoma       Date:  2012-10-03

9.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244

10.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.